Ansell Healthcare Products on Monday announced the release of Skyn Large following the success of Skyn, the first polyisoprene condom on the market, and due to high consumer demand for a larger Skyn product.

A drug originally developed by scientists in the Soviet Union to treat allergies and currently under investigation by Pfizer and Medivation did not yield significant results in a late-stage clinical trial of patients with Huntington disease, a disorder that leads to cognitive decline, the companies said Monday.

The Food and Drug Administration has approved an oral contraceptive made by Sandoz, the company said Friday.

Winn-Dixie on Monday announced that its pharmacy will offer specially designed medication disposal envelopes to help its customers safely dispose of unused, outdated or unwanted medications.

The Emerson Group announced that former Actavis executive Brad Blake has joined the company.

The Food and Drug Administration has granted tentative approval to a generic antibiotic made by Hi-Tech Pharmacal, the drug maker said Friday.

A Georgetown University Health Policy Institute study of Florida’s Medicaid Managed Care pilot program should raise doubts for states considering the use of for-profit managed care companies to reduce Medicaid costs, the National Community Pharmacists Association cautioned on Friday.

Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.

Watson announced that its subsidiary is seeking approval to market a generic version of a bacterial conjunctivitis treatment.

The Food and Drug Administration has approved a drug made by AstraZeneca for treating a rare form of thyroid cancer, the agency said.

U.S. marshals have seized more than $6 million in products distributed by Triad Group at the company’s facility in Hartland, Wis., the Food and Drug Administration reported Wednesday.

GNC Holdings on Wednesday announced the closing of its initial public offering of 25.9 million shares of its Class A common stock at a public offering price of $16 per share. GNC's Class A common stock began trading Friday, April 1, on the New York Stock Exchange under the ticker symbol "GNC."